Use of cladribine on a stent to prevent restenosis
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
May 8, 2003
app pub date -
Nov 12, 2002
filing date -
Feb 25, 2000
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
The current invention comprises an approach to solving the clinical problem of restenosis, which involves the administration of the antiproliferative antineoplastic agent, cladribine, to patients undergoing PTCA or stent implantation. In one embodiment of the invention, cladribine is administered to patients systemically, either subcutaneously or intravenously. In another embodiment of the invention, cladribine is bound to the surface of a stent by means of incorporation within either a biodegradable or biostable polymeric coating. Alternatively, cladribine could be incorporated into a stent constructed with a grooved reservoir.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully